{"id":845709,"date":"2025-05-01T17:19:30","date_gmt":"2025-05-01T21:19:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"modified":"2025-05-01T17:19:30","modified_gmt":"2025-05-01T21:19:30","slug":"ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","title":{"rendered":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n WARREN, N.J.<\/span>
\n <\/span>, May 1, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025<\/span>, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.<\/p>\n

\n

\n
\n \"PTC
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The inducement grants were approved by PTC’s Compensation Committee on April\u00a025, 2025, and are being made as an inducement material to each employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

All stock option awards have an exercise price of\u00a0$49.53 per share, the closing price of PTC’s common stock on April\u00a025, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee’s continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee’s new hire date until fully vested, subject to the employee’s continued service with the company through the applicable vesting dates.<\/p>\n

\n ABOUT PTC THERAPEUTICS, INC.
<\/b>PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC’s ability to innovate new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at www.ptcbio.com<\/a>\u00a0and follow us on Facebook, X, and LinkedIn.<\/p>\n

\n For more information please contact:<\/b>\n <\/p>\n

\n Investors:
<\/b>
\n Ellen Cavaleri<\/span>
\n
+1 (615) 618-8228
ecavaleri@ptcbio.com<\/a><\/p>\n

\n Media:
<\/b>
\n Jeanine Clemente<\/span>
\n
+1 (908) 912-9406
jclemente@ptcbio.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302444417.html<\/a><\/p>\n

SOURCE PTC Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire WARREN, N.J. , May 1, 2025 \/PRNewswire\/ —\u00a0PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The inducement grants were approved by PTC’s Compensation Committee on April\u00a025, 2025, and are being made as an inducement material to each employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock … <\/p>\n

Continue reading “PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-845709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire WARREN, N.J. , May 1, 2025 \/PRNewswire\/ —\u00a0PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The inducement grants were approved by PTC’s Compensation Committee on April\u00a025, 2025, and are being made as an inducement material to each employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock … Continue reading "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-01T21:19:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-05-01T21:19:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2582388\\\/PTC_LOGO_Logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\",\"name\":\"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2582388\\\/PTC_LOGO_Logo_Logo.jpg\",\"datePublished\":\"2025-05-01T21:19:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2582388\\\/PTC_LOGO_Logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2582388\\\/PTC_LOGO_Logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","og_locale":"en_US","og_type":"article","og_title":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PR Newswire WARREN, N.J. , May 1, 2025 \/PRNewswire\/ —\u00a0PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The inducement grants were approved by PTC’s Compensation Committee on April\u00a025, 2025, and are being made as an inducement material to each employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock … Continue reading \"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-01T21:19:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-05-01T21:19:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"},"wordCount":369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/","name":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg","datePublished":"2025-05-01T21:19:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2582388\/PTC_LOGO_Logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=845709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=845709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=845709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=845709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}